[1] Garbe C et al. (2022), "European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022", European Journal of Cancer 2022; 170: 256-284, https://doi.org/10.1016/j.ejca.2022.03.008
[2] Pellacani G et al. (2022), "Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in MelanomaA Randomized Clinical Trial", JAMA Dermatol 2022 online, doi:10.1001/jamadermatol.2022.1570
[3] Luke J.J. et al. (2021), "LBA3_PR - Pembrolizumab versus placebo after complete resection of high-risk stage II melanoma: Efficacy and safety results from the KEYNOTE-716 double-blind phase III trial", Ann Oncol 2021; 32 (suppl_5): S1283-S1346, 10.1016/annonc/annonc741
[4] ClinicalTrials.gov,"Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma (NivoMela)", Identifier: NCT04309409